A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control.
about
New criteria for response assessment: role of minimal residual disease in multiple myelomaCuring myeloma at last: defining criteria and providing the evidence.Staging and prognostication of multiple myelomaIdentification of the potential risk factors for monoclonal gammopathy of undetermined significance of progression.Measuring disease levels in myeloma using flow cytometry in combination with other laboratory techniques: Lessons from the past 20 years at the Leeds Haematological Malignancy Diagnostic Service.Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical TrialsMultiple Myeloma Minimal Residual Disease.Assessment of minimal residual disease in myeloma and the need for a consensus approach.Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation methodCritical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality.Transplant-Ineligible Symptomatic but Indolent Multiple Myeloma Shows Better Prognosis with Conventional Agents.Current applications of multiparameter flow cytometry in plasma cell disorders.Relevance of sample preparation for flow cytometry.Maternal embryonic leucine zipper kinase is a novel target for proliferation-associated high-risk myeloma.Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients.Clinical Relevance of Multicolour Flow Cytometry in Plasma Cell Disorders.
P2860
Q27027512-D3497F89-BEDE-49A1-8E2D-E606A3F17A1DQ34508313-DE3118FC-7BA3-439F-8405-FAC993661813Q38183871-D552936A-7307-460C-A89A-84A307A0B29CQ38199534-827AACF4-2FC5-4646-815A-7182953E0563Q38543115-7F2F2CE8-7157-4095-881C-1298320CF65AQ38789282-8722B912-ED86-44F6-90AF-D35D7CEB742CQ38970590-CE737997-91AB-49AD-9709-227D7CA288C9Q41556524-4F533139-5703-4CCF-ACFE-068E2CE9ACEAQ41557109-DFB05C8A-B215-45EC-A4BE-FAAD917613CFQ42715379-A9F37E75-CBC5-4A2C-8FD0-EE0325BAA800Q47105516-CE6D3EEF-1B18-40FC-B3CE-93C5063C56E7Q47110039-A179BAEA-48C1-4924-A0F0-D22B162ED430Q48233434-6784F566-7739-4966-9443-E77ABF5C3291Q49869942-231A4157-1ED8-47C9-A1A4-6C0485ED0755Q50224356-05AA9B07-1EF1-4500-8840-393309034FB5Q51804210-FABC76BF-61A2-4F30-96D6-A268A6BB73B5
P2860
A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
A multiparameter flow cytometr ...... and long-term disease control.
@en
A multiparameter flow cytometr ...... and long-term disease control.
@nl
type
label
A multiparameter flow cytometr ...... and long-term disease control.
@en
A multiparameter flow cytometr ...... and long-term disease control.
@nl
prefLabel
A multiparameter flow cytometr ...... and long-term disease control.
@en
A multiparameter flow cytometr ...... and long-term disease control.
@nl
P2093
P2860
P50
P356
P1433
P1476
A multiparameter flow cytometr ...... and long-term disease control.
@en
P2093
A Gorosquieta
F De Arriba
Grupo Español de MM/Programa p ...... lignas Cooperative Study Group
J Díaz-Mediavilla
J F San Miguel
P2860
P2888
P304
P356
10.1038/LEU.2013.166
P577
2013-06-07T00:00:00Z